君实生物：公司已获得JS207与JS212联合用药的I/II期临床试验批准

Core Viewpoint - Junshi Biosciences has received approval for clinical trials of JS207 (PD-1/VEGF dual antibody) and JS212 (EGFR/HER3 dual antibody ADC) and plans to initiate related clinical research soon [1] Group 1: Clinical Trials - The company is currently conducting Phase II clinical trials for JS207, exploring combinations with chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types [1] - The company aims to explore various combination therapies to maximize the synergistic effects of its pipeline [1] Group 2: Development Challenges - The lengthy and complex process of drug development, from research to clinical trial approval and production, is subject to various uncertainties [1]